natgillin/translations-raw huggingface dataset:
In pigs, the product is intended for the treatment of mange mites, gastrointestinal roundworms, lungworms, kidney worms and sucking lice.
Pri prašičih je zdravilo namenjeno za zdravljenje infestacij z garjami, želodčno-črevesnimi glistami, pljučnimi črvi, ledvičnimi črvi in sesajočimi ušmi.
In cattle, the product is intended for the treatment and control of gastrointestinal roundworms, lungworms, eyeworms, warbles, lice and mange mites.
Pri govedu je zdravilo namenjeno za zdravljenje in nadzor infestacij z želodčno-črevesnimi glistami, pljučnimi črvi, očesnimi črvi, ličinkami zolja, ušmi in garjami.
Prontax 10 mg/ml solution for injection for cattle, sheep and pigs contains doramectin as active ingredient.
Zdravilo Prontax 10 mg/ml, raztopina za injiciranje za govedo, ovce in prašiče, vsebuje zdravilno učinkovino doramektin.
The ERA for pigs can stop at Phase I in accordance with the VICH guideline.
Ocena tveganja za okolje za prašiče se v skladu s smernico VICH lahko zaključi v fazi I. Za govedo in ovce je bilo potrebno ocenjevanje stopnje A faze II.
Overall summary of the scientific evaluation of Prontax 10 mg/ml solution for injection for cattle, sheep, and pigs and associated names
Splošni povzetek znanstvenega vrednotenja zdravila Prontax 10 mg/ml, raztopina za injiciranje za govedo, ovce in prašiče, in povezanih imen
Kidney: 60 μg/kg
60 μg/kg
Amendments in the relevant sections of the summary of product characteristics, labelling and package leaflet
Dopolnila, ki se vključijo v ustrezna poglavja povzetka glavnih značilnosti zdravila, označevanja in navodila za uporabo:
PIGS: Meat and offal:withdrawal period 56 days.
Meso in organi: 56 dni.
INN/Strength Animal species
INN/Jakost
Doramectin residues were below muscle MRL at the injection site 35 days after treatment.
Ostanki doramektina na mestu injiciranja so bili 35. dan po zdravljenju pod mejno vrednostjo ostankov za mišičje.
Doramectin residues were above the muscle MRL at the injection site in all animals at 35 days after administration, which is the last timepoint for which there is data.
Ostanki doramektina na mestu injiciranja so bili 35. dan po dajanju zdravila, kar je zadnja časovna točka, za katero so na voljo podatki, pri vseh živalih nad mejno vrednostjo ostankov za mišičje.
A GLP tissue depletion study from 2002 performed in cattle (34 animals) following two subcutaneous administrations of doramectin at the recommended dose of 200 µg/kg bw with an interval of 7 days between doses.
Študija izločanja ostankov iz tkiv, skladna z dobro laboratorijsko prakso, je bila izvedena leta 2002 pri govedu (34 živali) po dveh subkutanih dajanjih doramektina v priporočenem odmerku 200 µg/kg telesne mase, pri čemer je bil razmik med odmerkoma 7 dni.
The individual doramectin residues were below the MRL at the injection sites at 35 days after treatment.
Ostanki doramektina na mestu injiciranja so bili 35. dan po zdravljenju pri posameznih živalih pod mejno vrednostjo ostankov.
Milk: - The product is not permitted for use in lactating sheep used to produce milk for human consumption.
Mleko: zdravila se ne sme uporabljati pri živalih v laktaciji katerih mleko se uporablja v prehrani človeka, niti pri ovcah v presušitvi oziroma brejih živalih 70 dni pred porodom.
Individual doramectin residues were still above the muscle MRL at the injection site 49 days after administration, which is the last timepoint for which there is data.
Ostanki doramektina na mestu injiciranja 49. dan po dajanju zdravila, kar je zadnja časovna točka, za katero so na voljo podatki, so bili pri posameznih živalih še vedno nad mejno vrednostjo ostankov za mišičje.
Milk: - The product is not permitted for use in lactating cows used to produce milk for human consumption.
Mleko: zdravila se ne sme uporabljati pri živalih v laktaciji katerih mleko se uporablja v prehrani človeka niti pri kravah v presušitvi oziroma brejih telicah 60 dni pred porodom.
A GLP tissue depletion study from 1989 was performed in calves (3 groups of 4 animals) following a single subcutaneous administration of doramectin at the recommended dose of 200 µg/kg bw.
Študija izločanja ostankov iz tkiv, skladna z dobro laboratorijsko prakso, je bila izvedena leta 1989 pri teletih (3 skupine po 4 živali) po enkratnem subkutanem dajanju doramektina v priporočenem odmerku 200 µg/kg telesne mase.
A non-GLP tissue depletion study from 2003 was performed in cattle (24 animals) following a single subcutaneous administration of doramectin at the recommended dose of 200 µg/kg bw.
Študija izločanja ostankov iz tkiv, neskladna z dobro laboratorijsko prakso, je bila izvedena leta 2003 pri govedu (24 živali) po enkratnem subkutanem dajanju doramektina v priporočenem odmerku 200 µg/kg telesne mase.
Cattlesubcutaneous
4.11 Karenca
A GLP tissue depletion study from 1991 was performed in calves (18 animals) following a single subcutaneous administration of doramectin at the recommended dose of 200 µg/kg bw.
Študija izločanja ostankov iz tkiv, skladna z dobro laboratorijsko prakso, je bila izvedena leta 1991 pri teletih (18 živali) po enkratnem subkutanem dajanju doramektina v priporočenem odmerku 200 µg/kg telesne mase.
According to the VICH Guideline 38 Phase II, a Tier B assessment is required.
V skladu s smernico VICH 38 za fazo II je potrebno ocenjevanje v stopnji B. V prvem primeru kljub več izboljšanjem PKO tveganja za dafnide pri scenariju neposrednega izločanja ni bilo mogoče izključiti.
Fat: 150 μg/kg
150 μg/kg jetra:
CATTLE: Meat and offal:withdrawal period: 54 days.
GOVEDO: Meso in organi: 70 dni.
Liver: 100 μg/kg
100 μg/kg ledvice:
SHEEP: Meat and offal:withdrawal period: 63 days.
OVCE: Meso in organi: 70 dni.
Applicant
subkutano
1 Mean toxin neutralising titre obtained after repeated vaccination of a half dose in rabbits.
Srednji toksin nevtralizirajoči titer je določen po ponovljeni vakcinaciji s polovičnim odmerkom pri kuncih.
This summary was last updated in 11-2006.
Ta povzetek je bil nazadnje posodobljen 11-2006.
This side effect usually disappears within one week.
Ta neželeni učinek navadno izgine v enem tednu.
If pain persists for more than 12 hours after medical examination, the doctor should be contacted again.
Če bolečina vztraja več kot 12 ur po zdravniškem pregledu, je treba zdravnika ponovno obiskati.
Rarely, hypersensitivity (allergic) reactions may occur, which require treatment.
Redko lahko pride do reakcij prekomerne občutljivosti (alergije), ki zahtevajo zdravljenje.
The first laboratory study tested the dose needed to provide protection.
V prvi laboratorijski raziskavi so testirali odmerek, ki je potreben za zagotovitev zaščite.
If someone is accidentally injected with this product, they must seek immediate medical advice even if only a very small amount is injected.
Če je nekdo nenamerno prejel injekcijo tega zdravila, naj takoj poišče zdravniški nasvet, tudi če je bila vbrizgana zelo majhna količina.
The second injection is given 1 to 2 weeks before the expected date of whelping.
Drugo injekcijo damo 1 do 2 tedna pred pričakovanim dnevom kotitve.
Accidental injection may cause severe pain and swelling, particularly if injected into a joint or finger - rarely causing the loss of a finger.
Nenamerno vbrizganje lahko povzroči hudo bolečino in otekanje, predvsem če se zdravilo vbrizga v sklep ali prst - redko povzroči izgubo prsta.
The bitch should be revaccinated in the same way during each pregnancy.
Psico bi morali na enak način cepiti med vsako ponovno brejostjo.
When exposed to canine herpes virus later in life, the puppies will either not become infected or have a much less serious infection.
Pri izpostavitvi teh mladičev pasjemu herpesvirusu kasneje v življenju, se ti bodisi ne bodo okužili oziroma bo njihova okužba manj resna.
In one field trial the serological response (antibody production) was measured.
V enem izmed terenskih preizkušanj (tvorjenje protiteles) so merili serološke reakcije.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) EURICAN HERPES 205 EPAR summary for the public
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) EURICAN HERPES 205 Povzetek EPAR za javnost
Eurican Herpes 205 has been studied in three laboratory studies and two field trials.
Zdravilo Eurican Herpes 205 so raziskali v treh laboratorijskih raziskavah in dveh terenskih preizkušanjih.
The first injection is given either when the bitch is on heat or 7 -10 days after the date of mating.
Prvo injekcijo damo bodisi v času, ko se psica goni, ali od 7 do 10 dni po datumu parjenja.
In the other, a study was made of the effect of vaccination on the ability of bitches to breed in an infected kennel.
V drugem so raziskovali učinek cepljenja na sposobnost razplajanja psic v okuženem pesjaku.
Information on the prescription status of this product may be found on the labelling.
Podatki o statusu predpisovanja tega zdravila so odtisnjeni na škatli zdravila.
In the study to show the protection of puppies (from vaccinated bitches) from canine herpes virus, over 80% of the pups from the vaccinated bitches survived..
V raziskavi, katere namen je bil pokazati zaščito mladičev (zaradi cepljenja psic) pred pasjim herpesvirusom, je preživelo več kot 80 % mladičev cepljenih psic.
The Committee for Medicinal Products for Veterinary Use (CVMP) agreed that the benefits of Eurican Herpes 205 are greater than any risks to immunise healthy bitches against canine herpes virus.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je mnenja, da so koristi zdravila Eurican Herpes 205 večje od vseh tveganj pri imunizaciji zdravih psic na pasji herpesvirus.
The benefitrisk balance may be found in module 6 of this EPAR.
Razmerje med koristmi in tveganji je v modulu 6 tega Evropskega javnega poročila o oceni zdravila (EPAR).
The European Commission granted a marketing authorisation valid throughout the European Union, for Eurican Herpes 205 to Merial on 26 March 2001.
Evropska komisija je dovoljenje za promet z zdravilom Eurican Herpes 205, veljavno po vsej Evropski uniji, odobrila družbi Merial dne 26. marca 2001.
Eurican Herpes 205 is used to immunise pregnant bitches to prevent mortality, clinical signs and lesions in puppies caused by canine herpes virus infections acquired in the first few days of life.
Eurican Herpes 205 se uporablja za imunizacijo brejih psic, da bi tako preprečili smrtnost, klinične znake in lezije pri mladičih, ki jih povzroči okužba s pasjim herpesvirusom v prvih dneh življenja.
The last one has demonstrating that induction of antibodies is equivalent when bitches are vaccinated the day of heat or 7-10 days after mating.
Raziskava je pokazala, da je indukcija tvorjenja protiteles ustrezna, če se psice cepi na dan, ko se gonijo, ali od 7 do 10 dni po parjenju.
Here Eurican Herpes 205 was compared with no vaccination (controls).
V tej raziskavi zdravila Eurican Herpes 205 niso primerjali z drugimi cepivi (kontrola).
Other information about Eurican Herpes 205:
Druge informacije o zdravilu Eurican Herpes 205:
Eurican Herpes 205 contains the active substance canine herpes virus (F205 strain) antigens in a dose of 0.3 to 1.75 µg.
Eurican Herpes 205 vsebuje kot zdravilno učinkovino antigene pasjega herpesvirusa (sev F205) v odmerku od 0,3 do 1,75 µg.
The injection of Eurican Herpes 205 may cause temporary oedema (fluid under the skin) at the injection site in up to 10% of animals.
Injekcija zdravila Eurican Herpes 205 lahko povzroči nastanek začasnega edema (zbiranje tekočine pod kožo) na mestu vbrizganja pri največ 10 % živali.
Eurican Herpes 205 contains mineral oil.
Zdravilo Eurican Herpes 205 vsebuje mineralno olje.
The second study was carried out to show the protection of puppies from vaccinated bitches from canine herpe svirus.
Drugo raziskavo so izvedli, da bi dokazali zaščito mladičev pred pasjim herpesvirusom zaradi cepljenja psic.
Eurican Herpes 205 is intended to protect the puppies from this infection during the first few days of life.
Zdravilo Eurican Herpes 205 je namenjeno za zaščito mladičev pred omenjeno okužbo v prvih dneh življenja.
Eurican Herpes 205 is a powder and solvent that is made into an emulsion for injection.
Eurican Herpes 205 sestavljata prašek in vehikel za pripravo emulzije za injiciranje.
Eurican Herpes 205 is given as two 1 ml subcutaneous (under the skin) doses.
Eurican Herpes 205 damo kot dva 1 ml podkožna (subkutana) odmerka.
Eurican Herpes 205 showed good protection from canine herpes virus.
Zdravilo Eurican Herpes 205 je pokazalo dobro sposobnost zaščite pred pasjim herpesvirusom.
What benefit has Eurican Herpes 205 shown during the studies?
Kakšne koristi je zdravilo Eurican Herpes 205 izkazalo med raziskavami?
The Package Leaflet should be taken to the doctor.
K zdravniku nesite tudi Navodilo za uporabo.
When injected, this small exposure helps the dog's immune system to synthesize antibodies against the canine herpes virus and to neutralize it. Once vaccinated, bitches will, through colostrum, give those antibodies to puppies.
Pri vbrizganju pride do šibke izpostavitve virusu, ki imunskemu sistemu pomaga pri tvorjenju protiteles proti pasjemu herpesvirusu in s tem tudi pri njegovi nevtralizaciji.
Why has Eurican Herpes 205 been approved?
Zakaj je bilo zdravilo Eurican Herpes 205 odobreno?
They recommended that Eurican Herpes 205 should be given a marketing authorisation.
Odbor je priporočil odobritev dovoljenja za promet z zdravilom Eurican Herpes 205.
Eurican Herpes 205 contains small amounts of canine herpes virus antigens.
Zdravilo Eurican Herpes 205 vsebuje majhno količino pasjega herpesvirusa.
What is Eurican Herpes 205?
Kaj je zdravilo Eurican Herpes 205?
What is Eurican Herpes 205 used for?
Za kaj se zdravilo Eurican Herpes 205 uporablja?
How does Eurican Herpes 205 work?
Kako zdravilo Eurican Herpes 205 deluje?
What are the side effects of Eurican Herpes 205?
Kakšni so neželeni učinki zdravila Eurican Herpes 205?
How has the effectiveness of Eurican Herpes 205 been studied?
Kako je bilo zdravilo Eurican Herpes 205 raziskano?
09 October 2013
09. oktober 2013
The European Commission issued a decision on this opinion on 09 October 2013.
Evropska komisija je sklep v zvezi s tem mnenjem izdala 09. oktobra 2013.
The company wanted the authorisation to be recognised in Belgium, France, Germany, Luxembourg, Malta, Netherlands, Sweden and United Kingdom (the ‘concerned Member States').
Družba je želela, da se dovoljenje za promet z zdravilom prizna v Belgiji, Franciji, Nemčiji, Luksemburgu, na Malti, Nizozemskem, Švedskem in v Združenem kraljestvu (zadevne države članice).
The Committee also noted that the studies were performed by the applicant before the publication of recent updated guidance1 for products of this type.
Odbor je prav tako izpostavil, da je predlagatelj te študije opravil pred objavo zadnje posodobljene smernice 1za to vrsto zdravil.
However, the Member States were not able to reach an agreement and the Danish medicines regulatory agency referred the matter to the CHMP for arbitration on 21 December 2012.
Vendar države članice niso mogle doseči soglasja, zato je danska regulativna agencija za zdravila 21. decembra 2012 zadevo napotila na CHMP v arbitražo.
Two medicines are bioequivalent if they produce the same levels of the active substance in the body.
Dve zdravili sta biološko enakovredni, kadar dosegata enake ravni zdravilne učinkovine v telesu.
On 25 July 2013, the European Medicines Agency completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Methylphenidate Sandoz.
Evropska agencija za zdravila je 25. julija 2013 zaključila arbitražni postopek, do katerega je prišlo zaradi nesoglasja med državami članicami Evropske unije (EU) glede odobritve dovoljenja za promet z zdravilom Methylphenidate Sandoz.
Methylphenidate is a medicine that is used to treat children aged between 6 and 18 years of age who have ADHD (attention deficit/hyperactivity disorder), a condition in which children show a persistent inability to concentrate, hyperactivity and impulsive behaviour.
Metilfenidat je zdravilo, ki se uporablja pri otrocih, starih od 6 do 18 let, za zdravljenje motnje pomanjkanja pozornosti s hiperaktivnostjo (ADHD), pri kateri so prisotni stalna nezmožnost koncentracije, hiperaktivnost in impulzivno vedenje.
Methylphenidate Sandoz is a generic medicine based on a ‘reference medicine', Concerta, which is authorised in all the EU Member States.
Methylphenidate Sandoz je generično zdravilo na osnovi „referenčnega zdravila“ Concerta, ki je odobreno v vseh državah članicah EU.
Sandoz A/S submitted Methylphenidate Sandoz for mutual recognition on the basis of the initial authorisation granted by Denmark on 29 March 2012 and also valid through a decentralised procedure in Cyprus, Finland, Poland, Portugal and Spain, as well as Iceland and Norway.
Družba Sandoz A/S je predložila vlogo za pridobitev dovoljenja za promet z zdravilom Methylphenidate Sandoz po postopku z medsebojnim priznavanjem na podlagi prvotnega dovoljenja za promet z zdravilom, izdanega 29. marca 2012 na Danskem in prav tako veljavnega na Cipru, Finskem, Poljskem, Portugalskem in v Španiji v skladu z decentraliziranim postopkom.
Questions & Answers: Positions on specific questions addressed to the pharmacokinetics working party.
Odbor za zdravila za uporabo v humani medicini, Vprašanja in odgovori: stališča v zvezi z določenimi vprašanji, postavljenimi delovni skupini za farmakokinetiko.
Methylphenidate belongs to a group of medicines called ‘psychostimulants' and is thought to work by enhancing the activity of areas of the brain that control attention and concentration.
Metilfenidat spada v skupino zdravil, imenovanih „psihostimulansi“, ki delujejo tako, da izboljšajo delovanje delov možganov, ki nadzorujejo pozornost in koncentracijo.
Why was Methylphenidate Sandoz reviewed?
Zakaj je bilo zdravilo Methylphenidate Sandoz pregledano?
It is available as a modified-release tablet, which releases some of the active substance immediately (the ‘immediate-release phase') and the rest over several hours.
Na voljo je v obliki tablet s prirejenim sproščanjem, ki del zdravilne učinkovine sprostijo takoj (faza takojšnjega sproščanja), preostanek pa v več urah.
What is Methylphenidate Sandoz?
Kaj je zdravilo Methylphenidate Sandoz?
It has been available since the 1950s as both immediate-release tablets and capsules, which release methylphenidate straight away, and as modified-release tablets that release some or all of the active substance more slowly over several hours.
Na voljo je od petdesetih let 20. stoletja v obliki tablet in kapsul s takojšnjim sproščanjem, ki takoj sprostijo metilfenidat, ter tablet s prirejenim sproščanjem, ki sprostijo del ali celotno zdravilno učinkovino počasneje, v več urah.
Questions and answers on Methylphenidate Sandoz (methylphenidate hydrochloride, prolonged-release tablet 18, 36 and 54 mg)
Vprašanja in odgovori v zvezi z zdravilom Methylphenidate Sandoz (metilfenidatijev klorid, tableta s podaljšanim sproščanjem, 18, 36 in 54 mg)
Based on evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that the failure to show bioequivalence between Methylphenidate Sandoz and its reference medicine in the immediate-release phase under fed conditions were due to differences between patients in the effects of a high-fat meal on the way medicines are handled by the body, and not to differences between the formulations of the two medicinal products, and that bioequivalence to the reference medicinal product has been shown.
Na podlagi razpoložljivih podatkov in znanstvene razprave znotraj odbora je ta ugotovil, da biološke enakovrednosti med zdravilom Methylphenidate Sandoz in referenčnim zdravilom v fazi s takojšnjim sproščanjem ni bilo mogoče dokazati zaradi razlik med bolniki glede učinkov obroka z veliko vsebnostjo maščob na to, kako telo obdela zdravila, in ne zaradi razlik v formulacijah teh dveh zdravil, zato je sklenil, da je bila biološka enakovrednost referenčnemu zdravilu dokazana.
Requirements for demonstration of bioequivalence for generics of biphasic modified release formulations for oral use.
Zahteve za dokazovanje biološke enakovrednosti generičnih zdravil pri dvofaznih peroralnih formulacijah s prirejenim sproščanjem.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Methylphenidate Sandoz outweigh its risks, and the marketing authorisation granted in Denmark can be recognised in other Member States of the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Methylphenidate Sandoz večje od z njim povezanih tveganj ter da se lahko dovoljenje za promet, izdano na Danskem, odobri v drugih državah članicah EU.
The CHMP therefore concluded that the benefits of Methylphenidate Sandoz outweigh its risks and recommended that the marketing authorisation be granted in the concerned Member States.
CHMP je zato zaključil, da koristi zdravila Methylphenidate Sandoz odtehtajo z njim povezana tveganja, in priporočil, da se dovoljenje za promet z zdravilom odobri v zadevnih državah članicah.
The grounds for the referral were objections raised by Germany and the Netherlands who considered that the bioequivalence study carried out under fed conditions did not show that Methylphenidate Sandoz was bioequivalent for the immediate-release phase to its reference product.
Podlaga za napotitev so bili pomisleki Nemčije in Nizozemske, ki sta menili, da študija biološke enakovrednosti pri jemanju na poln želodec ni pokazala, da je faza takojšnjega sproščanja pri zdravilu Methylphenidate Sandoz biološko enakovredna referenčnemu zdravilu Ker je v informacijah o zdravilu navedeno, da se lahko tableta vzame s hrano ali brez nje, je bila za odobritev dovoljenja za promet z zdravilom potrebna študija o biološki enakovrednosti pri jemanju na poln želodec.
It is available as tablets (500 and 1,000 mg) and as an oral solution (100 mg/ml).
Na voljo je v obliki tablet (500 in 1 000 mg) in v obliki peroralne raztopine (100 mg/ml).
The total dose for the whole day should be less than 100 mg per kilogram body weight.
Skupni odmerek za cel dan mora biti manjši od 100 mg na kilogram telesne mase.
Over time, the excess iron can damage important organs such as the heart and liver.
Sčasoma lahko odvečno železo poškoduje pomembne organe, kot so srce in jetra.
Further information on Ferriprox can be found on the Agency's website: ema.europa.eu/en/medicines/human/EPAR/ferriprox.
Nadaljnje informacije za zdravilo Ferriprox so na voljo na spletni strani agencije: ema.europa.eu/en/medicines/human/EPAR/ferriprox.
The doctor may interrupt treatment if iron levels get too low.
Zdravnik lahko prekine zdravljenje, če se ravni železa spustijo prenizko.
The main measure of effectiveness was the change in the levels of ferritin in the blood.
Glavno merilo učinkovitosti je bila sprememba ravni feritina v krvi.
Patients with thalassaemia major need frequent blood transfusions.
Bolniki s talasemijo major pogosto potrebujejo transfuzijo krvi.
• on its own, when standard iron chelator treatment cannot be used or does not work well enough;
• samostojno, kadar standardnega zdravljenja s kelatorjem železa ni mogoče uporabiti ali ni dovolj učinkovito;
• in combination with another iron chelator, when treatment with one iron chelator on its own does not work or when iron levels need to be rapidly or intensively corrected to prevent or treat lifethreatening conditions (mainly affecting the heart).
• v kombinaciji z drugim kelatorjem železa, kadar zdravljenje z enim samim kelatorjem ne deluje ali kadar je treba ravni železa hitro ali intenzivno popraviti, da se prepreči ali zdravi življenjsko nevarno stanje (ki vpliva predvsem na srce).
Removing iron in this way helps to correct the iron overload and prevent damage from excess iron.
Odstranjevanje železa na ta način pomaga popraviti preobremenitev z železom in preprečiti škodo, ki nastane zaradi odvečnega železa.
What measures are being taken to ensure the safe and effective use of Ferriprox?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Ferriprox?
Deferoxamine was given by injection under the skin overnight.
Deferoksamin je bil dan z injiciranjem pod kožo čez noč.